Compare LAES & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAES | BNTC |
|---|---|---|
| Founded | 2022 | 1995 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.0M | 396.3M |
| IPO Year | 2022 | 2020 |
| Metric | LAES | BNTC |
|---|---|---|
| Price | $2.37 | $9.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $5.88 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 3.8M | 125.6K |
| Earning Date | 09-11-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $59.43 | N/A |
| Revenue Next Year | $41.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.99 | $9.26 |
| 52 Week High | $8.71 | $16.76 |
| Indicator | LAES | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 33.18 |
| Support Level | $2.34 | N/A |
| Resistance Level | $2.52 | $13.49 |
| Average True Range (ATR) | 0.09 | 0.72 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 53.85 | 16.93 |
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.